SARS-CoV-2 RBD of Spike protein, L452Q, F490S– lineage C.37 – Peru Lambda Variant

Reference:
Product nameSARS-CoV-2 RBD of Spike protein, L452Q, F490S– lineage C.37 – Peru Lambda Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /SynonymsC.37, Peru variant, Lambda variant, lineage C.37, Lambda variant, Peruvian variant, VUI-21JUN-01, GISAID clade GR/452Q.V1
ReferencePX-COV-P069
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on SARS-CoV-2 RBD of Spike protein, L452Q, F490S – C.37 lineage – Peruvian variant – Lambda variant

Lineage C.37 was designated as a new Variant Under Investigation (VUI-21JUN-01) by Public Health England (PHE) in June 2021. This lineage is believed to have originated in Peru as early as December 2020. Since then, it has spread globally and can currently be found at high prevalence in countries such as Chile, the United States of America, Mexico, Ecuador, and several European countries (UK, Germany, France, among others). Together with Peru, the first two countries observe the greatest rates of prevalence for this lineage.
This lineage was also recently named as Lambda variant by the World Health Organization (WHO). It carries several noteworthy mutations, particularly on the receptor-binding domain (RBD), the main driver of infection of the SARS-CoV-2 virus. The mutations comprise amino acid changes L452Q and F490S. Although data regarding the biological significance of these mutations remains scarce, it is hypothesized they are both associated with an enhanced ability to escape the organism’s neutralizing response. Mutation L452Q has previously been reported in some sequences of SARS-CoV-2 but never among the most prevalent variants of the virus. However, a similar mutation – L452R – has been detected in the variant of concern Delta (India), and in the variants of interest (VOI) Epsilon (Southern California) and Iota (New York). There is strong evidence suggesting that this particular mutation has increased SARS-CoV-2 infectivity and host immune evasion potency. In contrast, mutation F490S appears to derive from the Alpha variant (UK), and it is predicted to further improve the ability to evade the immune system. Early studies revealed this new variant displays a reduced sensitivity to convalescent plasma. However, further studies are necessary to elucidate how this new set of mutations will affect the effectiveness of current vaccines.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 RBD of Spike protein, L452Q, F490S– lineage C.37 – Peru Lambda Variant”

Your email address will not be published. Required fields are marked *

Related products

Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031-SIL 1500€
Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032-SIL 1500€
Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033-SIL 1500€
Stable Isotope Labeled Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Stable Isotope Labeled Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637-SIL 1500€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 230€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.